XENT News and Press, Intersect ENT Inc. From 10/07/19

Intersect ENT (NASDAQ: XENT ) slumps  26%  premarket on light volume in reaction to unsuccessful results from the randomized ASCEND study evaluating its drug-coated sinus balloon for dilating the frontal sinus ostium to reduce post-balloon dilation edema via the localized deliver...

Intersect ENT®, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced results from a study of the company’s ASCEND investigational drug-coated sinus balloon. The ASCEND study is the first prospective, r...

Intersect ENT, Inc. (XENT) Q2 2019 Earnings Conference Call August 1, 2019 4:30 PM ET Company Participants Jeri Hilleman – Chief Financial Officer Kieran Gallahue – Executive Chairman Tom West – President and Chief Executive Officer Conference Call Partici...

Stericycle (NASDAQ: SRCL ) upgraded to Neutral with a $44 (flat) price target at Baird. More news on: Stericycle, Inc., Abiomed, Inc., Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks on the move, , Read more ...

Intersect ENT, Inc. (NASDAQ: XENT ): Q2 GAAP EPS of -$0.36 misses by $0.03 . More news on: Intersect ENT, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

CMS Assigns New J Code for SINUVA and PROPEL, Effective October 1 Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2019. In addition, the...

PROPEL Mini Delivery System Designed to Facilitate Implant Placement in the Ethmoid Sinus Intersect ENT ® , Inc. (Nasdaq:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that the company has received approval from t...

Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release second quarter financial results on August 1, 2019. The company expects to issue the release at approximately 4:00 p.m. ET and m...

Alder BioPharmaceuticals (NASDAQ: ALDR ) resumed with Neutral rating and $14 (22% upside) price target at Credit Suisse. Shares up 1% premarket. More news on: Alder BioPharmaceuticals, Inc., HMS Holdings Corp., DaVita Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Jeryl Hilleman to Step Down as CFO as Part of Planned Transition in 2020 Intersect ENT ® , Inc. (Nasdaq:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the appointment of Thomas (“Tom”) A. West as Pre...